Ophthotech Corp (OPHT) Tops Q1 EPS by 4c

Ophthotech Corp (NASDAQ: OPHT) reported Q1 EPS of ($0.36), $0.04 better than the analyst estimate of ($0.40).

“We continue to build on our Zimura program with on-going clinical trials in wet age related macular degeneration (AMD) with patient recruitment completed and topline data expected by the end of 2018, in geographic atrophy secondary to dry AMD where recruitment is on-track for topline data in the second half of 2019 and in autosomal recessive Stargardt disease which began enrolling patients earlier in the year,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech. “In parallel, we are excited to have initiated our first innovative gene therapy program in collaboration with Horae Gene Therapy Center at the University of Massachusetts Medical School to treat orphan degenerative retinal diseases. A key aspect of our strategy is to continue to build on this momentum to uncover novel and differentiating technologies and product candidates through collaborations with leading companies and academic institutions from around the world.”

For earnings history and earnings-related data on Ophthotech Corp (OPHT) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• OSI Systems (OSIS) Tops Q3 EPS by 6c
• United Bankshares (UBSI) Misses Q1 EPS by 1c